Yingguang Li

Title: Innovations of Yingguang Li in Quinazoline-7-Ether Compounds

Introduction

Yingguang Li is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of medicinal chemistry, particularly through his innovative work on quinazoline-7-ether compounds. His research focuses on developing therapeutic agents that target receptor protein tyrosine kinases (RTK), which are implicated in various diseases.

Latest Patents

Yingguang Li holds a patent for quinazoline-7-ether compounds and methods of use. This invention provides quinazoline-7-ether derivatives, specifically 4-anilinyl-6-butenamido-quinazoline-7-ether derivatives. These compounds serve as inhibitors of RTK activity, making them useful in treating hyperproliferative diseases, including cancer. The patent also outlines methods for preparing these quinazoline derivatives and their application as therapeutic agents, either alone or in combination with other drugs.

Career Highlights

Yingguang Li is currently associated with Newgen Therapeutics, Inc., where he continues to advance his research in the field of drug development. His work has the potential to impact the treatment landscape for diseases where RTK activity plays a critical role.

Collaborations

Yingguang Li collaborates with esteemed colleagues, including Wang Shen and Wei Xiao, to further enhance the research and development of innovative therapeutic solutions.

Conclusion

Yingguang Li's contributions to the field of medicinal chemistry, particularly through his patent on quinazoline-7-ether compounds, highlight his role as an influential inventor. His work promises to provide new avenues for treating diseases associated with RTK activity.